Puma Biotechnology Inc
Suletud
SektorTervishoid
9.08 -0.87
Ülevaade
Aktsiahinna muutus
24h
Min
8.9
Max
9.16
Sissetulek | 12M 8.2M |
|---|---|
Müük | 12M 57M |
P/E Sektori keskmine | 18.726 56.597 |
Aktsiakasum | 0.16 |
Kasumimarginaal | 14.493 |
Töötajad | 179 |
EBITDA | 14M 14M |
Järgmine tulemuste avaldamine | 5. nov 2026 |
|---|
Turukapital | 89M 493M |
|---|---|
Eelmine avamishind | 9.95 |
Eelmine sulgemishind | 9.08 |
Uudiste sentiment
By Acuity
50%
50%
136 / 339 Pingereas Healthcare
Puma Biotechnology Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Puma Biotechnology Inc Prognoos
Sentiment
By Acuity
136 / 339 Pingereas Tervishoid
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Üle keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.